Literature DB >> 7927249

Cerebral phosphorus-31 magnetic resonance spectroscopy in patients with chronic hepatic encephalopathy.

S D Taylor-Robinson1, J Sargentoni, R J Mallalieu, J D Bell, D J Bryant, G A Coutts, M Y Morgan.   

Abstract

Cerebral phosphorus-31 magnetic resonance spectroscopy was undertaken in 33 patients with biopsy-proven cirrhosis: 6 had no evidence of neuropsychiatric impairment on standard clinical, psychometric and electrophysiological testing; 8 had evidence of subclinical hepatic encephalopathy; and 19 were classified as having overt hepatic encephalopathy. The reference population comprised 15 healthy volunteers. Unlocalized spectra were acquired from the entire head with a 45-degree pulse angle and repetition times of 1 and 5 sec. Spectra localized to the basal ganglia were acquired with a 45-degree pulse angle and a repetition time of 1 sec. Peak area ratios of phosphomonoesters, inorganic phosphate, phosphodiesters and phosphocreatine relative to beta-ATP were measured in the spectra acquired. We noted no consistent change in the ratios of inorganic phosphate to ATP and phosphocreatine to ATP. Mean values of the ratios of phosphomonoesters to ATP and phosphodiesters to ATP were significantly lower in the total patient population than in the reference population, and they correlated with the patients' neuropsychiatric status. Thus we found no significant reductions in the mean ratios of phosphomonoesters to ATP and phosphodiesters to ATP in patients who were neuropsychiatrically unimpaired, but significant reductions were observed in the mean ratios of phosphomonoesters to ATP and phosphodiesters to ATP in patients with both subclinical and overt hepatic encephalopathy. The most marked reductions in these metabolite ratios were observed in patients with overt encephalopathy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7927249

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  17 in total

Review 1.  Alterations of neurotransmitter-related gene expression in human and experimental portal-systemic encephalopathy.

Authors:  R F Butterworth
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

Review 2.  Neurotransmitter dysfunction in hepatic encephalopathy: new approaches and new findings.

Authors:  R F Butterworth
Journal:  Metab Brain Dis       Date:  2001-06       Impact factor: 3.584

Review 3.  Clinical significance of basal ganglia alterations at brain MRI and 1H MRS in cirrhosis and role in the pathogenesis of hepatic encephalopathy.

Authors:  Laurent Spahr; Pierre R Burkhard; Hannelore Grötzsch; Antoine Hadengue
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

4.  Role of Magnetic Resonance in Understanding the Pathogenesis of Hepatic Encephalopathy.

Authors:  A Huda; R K Gupta; N Rajakumar; M A Thomas
Journal:  Magn Reson Insights       Date:  2008

Review 5.  Characteristics of minimal hepatic encephalopathy.

Authors:  Piero Amodio; Sara Montagnese; Angelo Gatta; Marsha Y Morgan
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

Review 6.  Energy metabolism in brain cells: effects of elevated ammonia concentrations.

Authors:  Leif Hertz; Geeta Kala
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

Review 7.  The role of magnetic resonance imaging and spectroscopy in hepatic encephalopathy.

Authors:  Mark J W McPhail; Simon D Taylor-Robinson
Journal:  Metab Brain Dis       Date:  2010-03-11       Impact factor: 3.584

Review 8.  Magnetic Resonance Spectroscopy: Principles and Techniques: Lessons for Clinicians.

Authors:  Joshua M Tognarelli; Mahvish Dawood; Mohamed I F Shariff; Vijay P B Grover; Mary M E Crossey; I Jane Cox; Simon D Taylor-Robinson; Mark J W McPhail
Journal:  J Clin Exp Hepatol       Date:  2015-11-12

9.  MR imaging and spectroscopy of the basal ganglia in chronic liver disease: correlation of T1-weighted contrast measurements with abnormalities in proton and phosphorus-31 MR spectra.

Authors:  S D Taylor-Robinson; J Sargentoni; A Oatridge; D J Bryant; J V Hajnal; C D Marcus; J P Seery; H J Hodgson; N M deSouza
Journal:  Metab Brain Dis       Date:  1996-09       Impact factor: 3.584

Review 10.  Effects of hyperammonaemia on brain function.

Authors:  R F Butterworth
Journal:  J Inherit Metab Dis       Date:  1998       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.